Treatment

A recent retrospective observational study examined adults with type 2 diabetes treated with GLP-1 receptor agonists and found important nutritional and body composition concerns alongside weight loss.

"Over 20 % had nutritional deficiencies diagnosed within one-year of starting GLP-1RA treatment."

Key points

• Use of GLP-1 receptor agonists was associated with loss of lean muscle mass, not just fat mass.

In this head-to-head trial, mazdutide outperformed dulaglutide on both glycemic control and weight reduction in adults with type 2 diabetes over 28 weeks, with a safety profile similar to other GLP-based therapies.

pubmed.ncbi.nlm.nih.gov

Mazdutide is a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D) ¹. This study assessed the efficacy and safety of mazdutide versus dulaglutide in participants with T2D on background oral anti-diabetic drugs. In thi …

Diabetes drugs may be changing cancer in surprising ways – new findings show that medications commonly used in type 2 diabetes not only impact glucose and weight control but might also influence cancer risk. Researchers are examining how these therapies might either reduce or inadvertently affect risks for multiple cancer types (e.g., liver, colorectal, breast), pointing to mechanisms beyond traditional metabolic control.

https://www.sciencedaily.com/releases/2025/12/251226045322.htm

Understand how GLP-1 medications like semaglutide and tirzepatide work - and how to eat, exercise, and stay healthy while using them.

✅ Tips for meal planning, protein intake, and hydration

🏋️‍♀️ Exercise strategies to preserve lean muscle

⚖️ Guidance on avoiding side effects and maintaining results

Explore this and other trusted patient resources at the T2D Network

🔗 Read more: https://jamanetwork.com/journals/jamainternalmedicine